Le Lézard
Classified in: Health
Subject: TRI

Intezyne Closes Oversubscribed $10M Series A Financing to Drive Rapid Oncology Portfolio Development

TAMPA, Fla., Oct. 6, 2017 /PRNewswire/ -- Intezyne Technologies, a clinical-stage biopharmaceutical company developing novel anti-cancer therapies, announced that it closed an oversubscribed $10M Series A Preferred round lead by existing investor Gaston Capital Healthcare Fund (GCHF). As part of the financing, David K. Robb, President and Chief Operating Officer (COO) at Gaston Capital, and Glenn Walthall, Chief Investment Officer (CIO) at Gaston Capital, joined Intezyne's Board of Directors.

Intezyne currently has two clinical-stage programs: IT-139, a novel Cancer Resistance Pathway (CRP) inhibitor for the treatment of pancreatic, gastric and BRAF-mutated cancers (including BRAF-mutated melanoma, lung cancer and thyroid cancer) in combination with existing anti-cancer therapies, and IT-141, a novel topoisomerase I (TOP-I) inhibitor for the treatment of colorectal and breast cancers. IT-139 was previously granted an Orphan Drug Designation (ODD) in the treatment of pancreatic cancer, of the most challenging-to-treat and deadliest forms of cancer, with 1-year and 5-year survival rates of only 20% and 8%, respectively. Gastric (stomach) cancer, while relatively rare in the United States, remains the fifth most common cancer and second most frequent cause of cancer death worldwide, with a 5-year survival rate of patients with advanced gastric cancer of a meager 3%. Preclinical data in both indications, supported by a previously completed Phase 1 safety study, suggest that IT-139 could meaningfully improve patient outcomes.

"This successful financing round puts the company on solid footing as we advance IT-139 and IT-141 through Phase 1/2 trials," said CEO Dr. Kevin Sill. "With compelling data and robust development rationales in a variety of different indications, our ongoing challenge is deciding which indications to prioritize in order to bring these potentially promising therapies to both patients and physicians as expediently as possible."

"In the coming months, we will be seeking additional capital from respected healthcare-focused institutional investors in a soon-to-be-launched $30M Series B Preferred round," said CFO E. Russell McAllister. "The Series B Preferred round is designed to fully fund the company through multiple Phase 2 trials, which should generate the data necessary for one or more lucrative development and commercialization partnerships and, subsequently, a compelling initial public offering (IPO). In the interim, we thank both existing and new investors in the Series A Preferred round for their enthusiastic support of Intezyne."

CEO Dr. Kevin Sill added, "Russell and I will be attending two major industry conferences in order to meet with investors and potential strategic partners: the BIO Investor Forum in San Francisco on October 16-18 and BIO-Europe in Berlin on November 6-8. We welcome any interest that investors, strategic partners, academic collaborators and clinical investigators might have in learning about our development programs."

For more information, please visit the Company's website at www.intezyne.com.


E. Russell McAllister, CFO

179461@email4pr.com, (813) 910-2120


SOURCE Intezyne Technologies, Inc.

These press releases may also interest you

at 09:02
Phosphorus, a leader in diagnostic and bioinformatic solutions for clinical Next Generation Sequencing (NGS), announced today, at the National Lipid Association Fall Clinical Lipid Update meeting, the launch of an expanded genetic test for inherited...

at 09:00
SpringCM, a DocuSign company, today announced that it has launched a social media campaign to raise money for New Genes, a not-for-profit organization dedicated to gene replacement therapy to address terminal childhood diseases. The campaign runs...

at 09:00
LOMA LINDA, Calif., Sept. 21, 2018 /PRNewswire-PRWeb/ -- Children with severe injuries tend to achieve more therapy-related progress, go home and rejoin their communities sooner as a result of a unique and proven treatment program at Totally Kids...

at 09:00
Thomas Rapisardo, M.D., today received the first annual Healthcare Hero Award from The Independence Fund for his exemplary service and dedication to America's wounded, ill, and injured Veterans. Rapisardo retired as a Primary Care Physician at the...

at 09:00
ORLANDO, Fla., Sept. 21, 2018 /PRNewswire-PRWeb/ -- MLX Fresh is a chiropractic and networking event that takes place on, October 18-20th, at the Omni Atlanta Hotel at CNN Center in Atlanta, Ga. MLX Fresh brings together chiropractor doctors,...

at 09:00
Sustainable Healthy Communities (SHC), a wholly owned subsidiary of the National Minority Quality Forum (NMQF), today announced a new population health initiative aimed at improving patient outcomes in underserved communities. The initiative is...

News published on 6 october 2017 at 08:30 and distributed by: